The International Journal of Biochemistry & Cell Biology
ReviewTowards the understanding of the local hematopoietic bone marrow renin-angiotensin system
Introduction
After the introduction of first angiotensin-converting enzyme (ACE) inhibitor, captopril, into the clinical practice, a marked progress occurred in the treatment of essential hypertension. Substantial studies led to development of new ACE inhibitors and angiotensin (Ang) II receptor antagonist and widespread use of those agents in a variety of indications beyond hypertension. However, several untoward effects including angioedema, rash and cough observed during ACE inhibitor therapy. Several observations also revealed that ACE inhibitors were associated with anemia and leukopenia (Nomura et al., 1996, Nomura et al., 1996; Vasku et al., 1998). The suppressive action of ACE inhibitors on normal erythropoiesis was demonstrated in hypertensive patients with kidney diseases suggesting that ACE inhibitors have disturbing effects on hematopoiesis (Nomura et al., 1996, Nomura et al., 1996, Rell et al., 1994). In the postrenal transplant erythrocytosis, ACE inhibitors and AT1 receptor antagonist (losartan) have effectively reduced hematocrit levels (Rell et al., 1994; Conlon, Smith, Butterly, & Brennan, 1996). Moreover, renin and aldosterone levels were threefold greater in chronic obstructive pulmonary disease (COPD) patients with secondary erythrocytosis than in CPOD patients with normal hematocrit values, indicating that activation of renin-angiotensin system (RAS) is associated with the development of erythrocytosis (Vlahakos et al., 1999). Regarding the effects of Ang II as a locally active growth factor in several tissues, we proposed the hypothesis for the presence of a local RAS in the bone marrow in 1996 (Haznedaroglu, Tuncer, & Gursoy, 1996). According to this hypothesis, there exists a locally active, intrinsic RAS in the bone marrow that might functionally affect the growth of hematopoietic colonies, cellular production, proliferation, and differentiation in physiological and pathological states, as in other tissues (Huckle & Earp, 1994). Since then, a number of investigations have been reported regarding the interactions of RAS and hematopoiesis (Hajek et al., 1999; Rodgers, Xiong, Steer, & DiZerega, 2000). The aim of this review is to briefly summarize the scientific background and the ‘State of the Art’ of the local bone marrow RAS.
Section snippets
Scientific background of the local hematopoietic bone marrow RAS
The historical view of RAS as the solely circulating endocrine system has now been expanded to embrace a broader concept that includes organ and tissue-based systems that perform paracrine and autocrine functions. Many studies have provided evidence for the locally operating RASs particularly in the cardiac, vascular and renal tissues (Danser et al., 1999, Dostal and Baker, 1999, Fischer et al., 1998, Holtz and Goetz, 1994, Iwai et al., 1988, Kifor and Dzau, 1987, Ruzicka and Leenen, 1997, So
RAS elements and hematopoietic system: initial clues
Several blood cells have been shown to carry essential RAS elements. Renin is expressed in circulating rat macrophage/monocyte cells (Iwai, Inagami, Ohmichi, & Kinoshita, 1996). Rat leukocytes in the bloodstream express the angiotensinogen gene, synthesize and release angiotensinogen with the capability to generate angiotensin (Gomez et al., 1993), although angiotensin generation could not be proven in human leukocytes (Davis, Liyou, & Johnson, 1998). On the other hand, angiotensinogen was
Cumulating evidences for the local hematopoietic bone marrow RAS
Evidence is now really accumulating to indicate the existence of a local RAS in the bone marrow, which may be operative in normal and malignant hematopoiesis with sensitivity to pharmacological maneuvers (Table 1). Ang II, through interacting with AT1 receptor enhances erythroid differentiation in the bone marrow. Ang II-stimulated erythroid progenitors formed significantly higher numbers of burst-forming unit-erythroid (BFU-E) colonies in normal human erythropoiesis. This stimulatory effect of
The RAS elements in pathological hematopoiesis
Furthermore, there is preliminary evidence that RAS may affect pathological/neoplastic hematopoiesis in the bone marrow. A renin-like enzyme activity converting angiotensinogen to angiotensin I was determined in leukemic blast cells (Wulf et al., 1996). Afterwards, a specific immunoreactive renin-like peptide of 47 kDa was isolated from AML blast cells (Wulf et al., 1998). In view of the emerging concepts on local RAS in different organs, this data claim attention to the role of renin-like
An analogical approach to the hematopoietic bone marrow RAS among other local RASs
Cardiac RAS is an analogical model for the hematopoietic bone marrow RAS (Haznedaroglu et al., 1996; Lijnen and Petrov, 1999a, Lijnen and Petrov, 1999c). Local myocardial RAS plays an important role in cardiac hypertrophy and remodeling via the activation of protein tyrosine kinases that involved in cell differentiation and proliferation (Akiyama et al., 1999). Locally produced Ang II may stimulate myocyte hypertrophy, ventricular remodeling, ameliorate myocyte contractile performance, and
Perspectives for the future: fill in the blanks of hematopoietic RAS
The identification of RAS components and Ang II receptors in the hematopoietic bone marrow may suggest the existence of an autocrine/paracrine system that has effects independent of Ang II derived from the circulatory system (Rodgers et al., 2000). As brilliantly reviewed for the local cardiac RAS by Dostal and Baker ‘to be functional, a local RAS should produce sufficient amounts of the autocrine and/or paracrine factor to elicit biological responses, contain the final effector (Ang II
Perspectives for the future: the local RAS-stem cell plasticity puzzle and research horizons
Taken together, some previously mentioned findings seem to be consistent with the locally active RAS in the bone marrow. Nevertheless, our knowledge about the local hematopoietic bone marrow RAS is still in “neonatal period”. Current perspective of this local system opens up new horizons for research regarding the pathogenesis of blood disorders.
Multipotent cardiac stem cells may renew the myocardium (Anversa & Nadal-Ginard, 2002). Transplantation of hematopoietic stem cells are capable of
References (98)
- et al.
Angiotensin II type 1 receptor blockade abolishes specific K(ATP)channel gene expression in rats with myocardial ischemia
Journal of Molecular and Cellular Cardiology
(2000) - et al.
. Ischemic cardiomyopathy and the cellular renin-angiotensin system
Journal of Heart and Lung Transplantation
(2000) - et al.
Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors
Blood
(1993) - et al.
The angiotensin AT2 receptor stimulates protein tyrosin phosphatase activity and mediates inhibition of particulate guanylate cyclase
Biochemical and Biophysical Research Communications
(1992) - et al.
Angiotensin II activates programmed myocyte cell death in vitro
Experimental Cell Research
(1997) - et al.
Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney
Kidney International
(1994) - et al.
Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide
Journal of Biological Chemistry
(1999) - et al.
Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent
Laboratory Investigation
(2000) - et al.
AT2 receptor stimulation induces generation of ceramides in PC12W cells
FEBS Letters
(1999) - et al.
A local renin-angiotensin system in the bone marrow
Medical Hypotheses
(1996)
Mitogen activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors
Journal of Biological Chemistry
Regulation of cell proliferation and growth by angiotensin II
Progress in Growth Factor Research
The cardiac renin-angiotensin system in heart failure
American Heart Journal
Local renin-angiotensin system and mitogen-activated protein kinase activation in rat aorta
European Journal of Pharmacology
Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes
Journal of Molecular and Cellular Cardiology
Normal neutrophil function in cathepsin G-deficient mice
Blood
The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: Improvement in mice survival and protection of bone marrow stem cells and progenitors
Blood
N-domain selectivity of angiotensin I-converting enzyme as assessed by structure-function studies of its highly selective substrate, N-acetyl-seryl-aspartyl-lysyl-proline
Biochemical Pharmacology
The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
Journal of Biological Chemistry
Catabolism of the hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro: A new insight into the physiological role of the angiotensin-I-converting enzyme N-active site
Bioorganic and Medicinal Chemistry
Angiotensin III increases MCP-1 and activates NF-κB and AP-1 in cultured mesangial and mononuclear cells
Kidney International
Angiotensin II, transforming growth factor-β1 and repair in the infarcted heart
Journal of Molecular and Cellular Cardiology
Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease
American Journal of Medicine
Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: Preliminary evidences
Hematology
Involvement of receptor-type tyrosine kinase gene families in cardiac hypertrophy
Journal of Hypertension
Myocyte renewal and ventricular remodelling
Nature
Angiotensin I-converting enzyme and metabolism of the haematological Peptide N-acetyl-seryl-aspartyl-lysyl-proline
Clinical and Experimental Pharmacology and Physiology
Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
Journal of Clinical Investigation
Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy
Hypertension
Paracrine actions of cardiac fibroblasts on cardiomyocytes: Implications for the cardiac renin-angiotensin system
American Journal of Cardiology
Angiotensin II that reduces the colony-forming ability of hematopoietic progenitors in serum free medium has an inverse effect in serum-supplemented medium
Stem Cells
Elastase and cathepsin G of human monocytes. Quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity
Journal of Immunology
The renin-angiotensin system in the endocrine pancreas
JOP
Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation
British Journal of Haematology
Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril
Stem Cells
Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures
Stem Cells
Angiotensin I-converting enzyme (ACE) polymorphism and ABO blood groups as factors codetermining plasma ACE activity
Experimental Hematology
Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice
Journal of Clinical Investigation
Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations
European Journal of Clinical Investigation
Losartan in post-transplant erythrocytosis
Nephrology Dialysis Transplantation
Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension
Journal of Hypertension
Is there a local renin-angiotensin system in the heart?
Cardiovascular Research
The angiotensinogen gene is not expressed in human leukocytes
American Journal of Hypertension
Angiotensin II induces apoptosis of human epithelial cells: Protective effect of nitric oxide
Circulation Research
The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function?
Circulation Research
The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
American Journal of Cardiology
Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes
American Journal of Physiology
In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation
Stem Cells
Cited by (100)
Hematopoietic bone marrow renin-angiotensin system in health and disease
2023, Angiotensin: From the Kidney to CoronavirusRenin–angiotensin–aldosterone system and blood pressure regulation
2022, Endocrine Hypertension: From Basic Science to Clinical PracticeCan SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature
2022, Hematology, Transfusion and Cell TherapyIron deficiency in chronic kidney disease patients with diabetes mellitus
2018, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :Several studies have concluded that renin-angiotensin axis blockers may interfere with the production of EPO [29–31]. Angiotensin 2 increases proliferation of early erythroid progenitors but not the progenitors of other cell lines and ARBs completely abolishes this effect [32]. These observations point to a possible inhibitory effect of these medications on bone marrow.
Erythropoietin Regulation by Angiotensin II
2017, Vitamins and HormonesCitation Excerpt :Expression of ACE (referred to as CD143) was identified as a marker for primitive lymphohematopoietic cells derived from human pluripotent stem cells (Jokubaitis et al., 2008; Zambidis et al., 2008). Increasing evidence points toward a “local” bone marrow RAS, in which all components of the RAS system are provided locally for the generation of Ang II, which is believed to play a role in normal hematopoiesis as well as some forms of myeloid leukemia (Beyazit et al., 2007; Haznedaroglu & Ozturk, 2003; Kato et al., 2015; Uz et al., 2014). Although a number of studies indicated that Ang II could directly affect hematopoiesis through receptors on hematopoietic progenitors, accumulating evidence also indicated that Ang II acted indirectly on hematopoiesis via regulation of gene expression of erythropoietin (EPO), a potent kidney glycopeptide hormone that is an essential growth factor regulating erythropoiesis (Dunn, Lo, & Donnelly, 2007; Elliott, Pham, & Macdougall, 2008; Freudenthaler, Lucht, Schenk, Brink, & Gleiter, 2000; Freudenthaler, Schreeb, Korner, & Gleiter, 1999; Vlahakos et al., 2010).
Preclinical and Clinical Development of Angiotensin Peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Application
2015, The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications